What is the current market price of momelotinib per box?

Momelotinib (Momelotinib) is a triple-target kinase inhibitor of JAK1/JAK2 and ACVR1. It is mainly used to treat myeloproliferative diseases such as intermediate- and high-risk myelofibrosis (MF). The drug can effectively relieve splenomegaly, improve anemia symptoms and reduce systemic symptoms. It is one of the more advanced targeted drugs for the treatment of myelofibrosis in recent years. At present, molotinib has not yet been approved for marketing in mainland China. If patients need the drug, they must obtain it through overseas channels.

In the international market, the original drug of molotinib was developed by the American pharmaceutical company Sierra Oncology (acquired by GSK) and is very expensive. According to the latest market data, the price of the US version of molotinib is as high as more than 200,000 yuan per box (specific specifications are usually 100 mg × 30 tablets). The high cost makes it difficult for many patients to afford it in the long term, so finding economically feasible alternatives has become a realistic choice for many patients.

Currently, there are no large-scale approved generics of molotinib on the market, but some pharmaceutical companies are actively promoting their generics. It should be noted that some patients mistakenly confused the "Lucius generic version of midostaurin" with the generic version of molotinib. In fact, Lucius produces another myeloproliferative disease drug "Midostaurin (Midostaurin)". This generic drug has been approved by the Ministry of Health of Laos. The specification is 100mg×30 tablets. The latest price is about RMB 2,000. Although the treatment areas of the two are similar, the drugs are not the same, and patients should strictly distinguish them when choosing drugs.

To sum up, as a new targeted drug that has not yet been launched in China, molotinib’s original drug is very expensive in overseas markets, costing more than 200,000 yuan per box. There is currently no generic version clearly on the market. Patients should obtain drug information through formal channels when choosing, and use drugs rationally under the guidance of professional doctors. At the same time, attention should also be paid to identifying the name and ingredients of the drug to avoid mistaking other similar drugs for molotinib. As the accessibility of medicines increases globally, more affordable alternatives are expected to emerge in the future.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib